vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and SolarMax Technology, Inc. (SMXT). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($57.3M vs $46.6M, roughly 1.2× SolarMax Technology, Inc.). SolarMax Technology, Inc. runs the higher net margin — -1.9% vs -83.0%, a 81.1% gap on every dollar of revenue. On growth, SolarMax Technology, Inc. posted the faster year-over-year revenue change (623.5% vs 36.9%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
SolarMax Technology, Inc. develops, manufactures and sells high-efficiency solar PV modules and clean energy systems. It serves residential, commercial and industrial clients in North America and key Asia-Pacific markets, offering installation and after-sales support to boost low-carbon energy use.
RYTM vs SMXT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $46.6M |
| Net Profit | $-47.5M | $-872.2K |
| Gross Margin | 91.6% | 2.7% |
| Operating Margin | -82.2% | -2.7% |
| Net Margin | -83.0% | -1.9% |
| Revenue YoY | 36.9% | 623.5% |
| Net Profit YoY | -9.6% | 77.7% |
| EPS (diluted) | $-0.73 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $46.6M | ||
| Q3 25 | $51.3M | $30.6M | ||
| Q2 25 | $48.5M | $6.9M | ||
| Q1 25 | $32.7M | $6.9M | ||
| Q4 24 | $41.8M | $6.4M | ||
| Q3 24 | $33.3M | $6.3M | ||
| Q2 24 | $29.1M | — | ||
| Q1 24 | $26.0M | — |
| Q4 25 | $-47.5M | $-872.2K | ||
| Q3 25 | $-52.9M | $-2.3M | ||
| Q2 25 | $-46.6M | $-1.9M | ||
| Q1 25 | $-49.5M | $-1.3M | ||
| Q4 24 | $-43.3M | $-3.9M | ||
| Q3 24 | $-43.6M | $-9.6M | ||
| Q2 24 | $-32.3M | — | ||
| Q1 24 | $-141.4M | — |
| Q4 25 | 91.6% | 2.7% | ||
| Q3 25 | 89.3% | 3.1% | ||
| Q2 25 | 88.6% | 8.8% | ||
| Q1 25 | 88.8% | 20.5% | ||
| Q4 24 | 90.9% | 14.5% | ||
| Q3 24 | 88.5% | 19.9% | ||
| Q2 24 | 89.9% | — | ||
| Q1 24 | 89.2% | — |
| Q4 25 | -82.2% | -2.7% | ||
| Q3 25 | -102.6% | -6.9% | ||
| Q2 25 | -93.4% | -25.7% | ||
| Q1 25 | -143.7% | -16.7% | ||
| Q4 24 | -98.6% | -27.9% | ||
| Q3 24 | -132.0% | -158.4% | ||
| Q2 24 | -139.2% | — | ||
| Q1 24 | -538.7% | — |
| Q4 25 | -83.0% | -1.9% | ||
| Q3 25 | -103.1% | -7.4% | ||
| Q2 25 | -96.1% | -27.6% | ||
| Q1 25 | -151.4% | -18.7% | ||
| Q4 24 | -103.6% | -60.6% | ||
| Q3 24 | -131.2% | -152.0% | ||
| Q2 24 | -110.9% | — | ||
| Q1 24 | -544.4% | — |
| Q4 25 | $-0.73 | $-0.02 | ||
| Q3 25 | $-0.82 | $-0.04 | ||
| Q2 25 | $-0.75 | $-0.04 | ||
| Q1 25 | $-0.81 | $-0.03 | ||
| Q4 24 | $-0.71 | $-0.07 | ||
| Q3 24 | $-0.73 | $-0.21 | ||
| Q2 24 | $-0.55 | — | ||
| Q1 24 | $-2.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $8.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $-12.2M |
| Total Assets | $480.2M | $91.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $8.0M | ||
| Q3 25 | $416.1M | $5.7M | ||
| Q2 25 | $291.0M | $1.9M | ||
| Q1 25 | $314.5M | $6.8M | ||
| Q4 24 | $320.6M | $7.1M | ||
| Q3 24 | $298.4M | $8.6M | ||
| Q2 24 | $319.1M | — | ||
| Q1 24 | $201.2M | — |
| Q4 25 | $139.1M | $-12.2M | ||
| Q3 25 | $148.8M | $-11.8M | ||
| Q2 25 | $-11.9M | $-15.1M | ||
| Q1 25 | $18.9M | $-15.9M | ||
| Q4 24 | $21.7M | $-15.1M | ||
| Q3 24 | $11.2M | $-10.9M | ||
| Q2 24 | $39.3M | — | ||
| Q1 24 | $61.6M | — |
| Q4 25 | $480.2M | $91.3M | ||
| Q3 25 | $506.9M | $58.7M | ||
| Q2 25 | $372.7M | $38.2M | ||
| Q1 25 | $386.7M | $38.6M | ||
| Q4 24 | $392.3M | $38.6M | ||
| Q3 24 | $363.6M | $43.0M | ||
| Q2 24 | $381.8M | — | ||
| Q1 24 | $258.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-2.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $-2.5M | ||
| Q3 25 | $-26.6M | $3.4M | ||
| Q2 25 | $-23.3M | $220.7K | ||
| Q1 25 | $-40.4M | $-601.1K | ||
| Q4 24 | $-18.8M | $-1.3M | ||
| Q3 24 | $-25.2M | $203.6K | ||
| Q2 24 | $-29.1M | — | ||
| Q1 24 | $-40.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYTM
Segment breakdown not available.
SMXT
| Yabucoa | $35.9M | 77% |
| Other | $10.7M | 23% |
